Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
Phase 2
Recruiting
- Conditions
- Epilepsy, GeneralizedEpilepsy, Absence
- Interventions
- Other: Placebo
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- NeuroPro Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06769659
- Locations
- 🇺🇸
Clinical Trials, Inc. (CTI), Little Rock, Arkansas, United States
A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- NeuroPro Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06525649
- Locations
- 🇺🇸
Clinical Trials, Inc. (CTI), Little Rock, Arkansas, United States
🇺🇸Idaho Comprehensive Epilepsy Center, Boise, Idaho, United States
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Alzheimer DiseaseEpilepsyEpilepsy Intractable
- Interventions
- Drug: NPT 2042 (bumetanide analog) or Matching Placebo
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- NeuroPro Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05503511
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
News
No news found